Authors: T. Kozák Authors‘ workplace: Oddělení klinické hematologie FNKV, Praha 1 Revmatologický ústav, Praha 2 Neurologická klinika VFN, Praha 3 Neurologická klinika FNKV, Praha 4 Ústav hematologie a krevní transfuze, Praha Published in: Čas. Lék. čes. 2000; : 329-333 Category:
Autoimmune diseases (AID) result from the impairment of the effector and/or recognition phase of the immuneresponse. The autoimmune process plays a crucial role in the pathogenesis of the systemic lupus erythematosus(SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), and their treatment is therefore largely based onimmunosuppression. However, some patients do not respond to its standard doses. The disease becomes intractablewith the survival rate comparable to that of some haematological malignancies, or patients become soon handicappedwith very poor quality of life, depending on continual administration of high doses of steroids. The new hope forthose patients becomes therapy with high dose myelo - and immuno-ablative chemotherapy with autologoushematopoietic progenitor cell support (PBPC). Tens of patients with intractable forms of AID were transplanted inthe pilot clinical studies with promising results. The most frequent indications included: SLE, SSc, and RA. Finalconclusion of the therapeutic effects will be drawn from the analysis of larger trails.
Key words: autoimmune diseases, systemic lupus erythematosus, haematological malignancies, myeloablation,
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
